Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease.
- DOI
- 10.1016/j.vaccine.2026.128770
- Published
- 2026 Aug 13
- Container
- Vaccine
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.vaccine.2026.128770,
title = {Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease.},
author = {Singer D and La EM and Dubois de Gennes C and Graham J and Grace M and Biundo E and Verelst F},
year = {2026},
journal = {Vaccine},
doi = {10.1016/j.vaccine.2026.128770},
url = {https://doi.org/10.1016/j.vaccine.2026.128770}
}RIS
TY - JOUR TI - Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease. AU - Singer D AU - La EM AU - Dubois de Gennes C AU - Graham J AU - Grace M AU - Biundo E AU - Verelst F PY - 2026 JO - Vaccine DO - 10.1016/j.vaccine.2026.128770 UR - https://doi.org/10.1016/j.vaccine.2026.128770 ER -
APA
D, S., EM, L., C, D. D. G., J, G., M, G., E, B., & F, V. (2026). Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease.. Vaccine. https://doi.org/10.1016/j.vaccine.2026.128770
Source records
- pubmed · retrieved 2026-09-26T23:57:17.992Z